News | April 14, 2025
Nureca’s manufacturing subsidiary secures USFDA registration
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
Padmanabhan brings over two decades of extensive experience in FMCG sector
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
The company does not expect this development to have any material impact on the current business operations
The supply of these goods is set to commence within the first quarter of FY26
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Subscribe To Our Newsletter & Stay Updated
